March 12th 2024
Individuals included in the study reported positive changes in fatigue, and disease activity displayed endoscopic and histologic remission.
FDA Approves Upadacitinib for Adults With Moderately to Severely Active Crohn Disease
May 18th 2023In clinical trials of patients with Crohn disease, upadacitinib demonstrated early and long-term symptom relief, as well a visible reduction of damage to the intestinal lining caused by excess inflammation.
Read More
Risankizumab Meets Primary Endpoint of Clinical Remission for Moderate to Severe Ulcerative Colitis
March 28th 2023The results of the INSPIRE trial demonstrated that 20.3% of individuals receiving risankizumab (Skyrizi) achieved clinical remission compared to 6.2% of individuals who received the placebo.
Read More